BIO.BE

Bio.Be is the federation of Belgian companies active in the biosciences and is part of essenscia (chemicals and life sciences).
Bio.Be represents the interests of its members as regards legislation and standards at various policy levels (Belgium, EU, OECD).
Its mission is to create a stable legal framework in line with the trend for innovation, an essential factor for the economic sustainability and growth of employment in this sector.

To this end, Bio.Be keeps a close eye on:

  • policy in Belgium and organises consultation with the policymakers*;
  • European policy, as the national association contact point (NAC) of EuropaBio - the European biotechnology federation;
  • consultation on biotechnology within the OECD,
so that it is continuously able to establish benchmarks and anticipate the needs of its members.

Bio.Be can rely on the synergy within the essenscia group (product groups and pharma.be) and has access to the available expertise via the SME bureau; the patent unit, Invest in
biopharma, REACH, FISCH, BIOCHEM and CINBIOS projects and the extensive network of partners (VBO, VOKA, UWE, BECI, CEFIC, Business Europe).

* Bio.be is also part of the high-level group essenscia/federal government and R&D biopharma platform/federal government

NEWS:THE ESSENSCIA/BIO.BE GENERAL ASSEMBLY AND SEMINAR (18.02.14)
                       
The essenscia/bio.be General Assembly and seminar (18.02.14) was a success. 7 political parties (OpenVLD, CD&V, Groen, NVA, CdH, MR, Ecolo) participated in the debate and explained their intentions about innovation and biotechnology. The debate was lead by Mr. Van Biervliet (VIB) and MR. De Kerpel (KBC Securities). Starting point were our Memorandum, Annual Report,  testimonials from our companies (see video below) and the presentations of  Deloitte (Scientific and Economic footprint of the Flemish Biotech), NautaDutilh (Belgian TTOs and their spin-offs. A match made in heaven?) and Biocom (The Biotech sector in Switzerland, Austria and Germany, a OECD study). This gave a good view of the current situation in Belgium and abroad, as well as what the policy should be to keep our biotech sector on the top level.

EFIB, the ‘European Forum for industrial biotechnology and biobased economy’ 1&2-10-2013 Brussels



EFIB, the ‘European Forum for industrial biotechnology and biobased economy’, taking place in Brussels, October 1 and 2, 2013, in cooperation with EuropaBio and essenscia/bio.be, was a success. This was also due to the active cooperation by some of our companies as Galactic, Ecover, Solvay, SNS Lavalin, Clever Consult and Proviron, as well as by our partners of our  Belgianbooth@EFIB : Greenwin, Valbiom, essenscia wallonie, GBEV, FlandersBio, Cinbios, Fisch en essenscia vlaanderen. In his videomessage,

Prime Minister Di Rupo stated that transition and innovation are the key elements for our future and the sustainable use of biomass is there part of.  He acknowledged that the federal government has still some tasks to do, this based on the essenscia/bio.be study “Towards a Belgian and regional strategy for a biobased economy”. We ask also a better coordination within the federal administration and the establishment of a global vision in coordination with the regions.

The necessity of stability and legal security for this sector on a long term is for Mr. Wim Michiels, CEO of Proviron, the most important issue.  You see him here in discussion with Mr. Antonio di Guilio,  DG Research, European Commission by during the final debate.

   

Interaction with its members

Bio.Be interacts directly with its members though its three vertical working groups:
  1. Health or red biotechnology
  2. Agriculture or green biotechnology
  3. Biobased or white biotechnology
and through its horizontal working groups on ISO/CEN STANDARDS, INTELLECTUAL PROPERTY, START-UPS AND SMES. The positions adopted are passed on via the Bio.Be issue sheets**.

Bio.Be:
  • organises the training courses required, both for its members and for the relevant stakeholders.
  • promotes and represents its members in other relevant organisations and bodies at home and abroad.
  • cooperates with other federations, network organisations, academics and various other players and facilitates consultation among them.
**Cells and tissues (ATMPs, Hospital exemption), Clinical trials, Biosimilars, Orphan drugs; Coexistence, Low level presence, Implementing regulation, Socio-economic, Re-Nationalisation; Biofuels, Biomass, Waste legislation, Ecolab, Reach; ISO Biotechnology, CEN biobased, IP biotechnology, Strategy biobased economy.